Skip to Content
Search Menu

Osimertinib for T790M-positive og -negative pasienter med EGFR-mutert ikke-småcellet lungekreft

/ Inger Johanne Zwicky Eide
Onkologi / Hematologi

Uføretrygdete langtidsoverlevere etter kreft i livmorhalsen

/ Alv A. Dahl / Anne Gry Bentzen / Cecilie E. Kiserud / Rita Steen / Siri Lothe Hess / Sophie D. Fosså
Onkologi / Hematologi

Kreft og palliasjon – integrasjon av onkologi og palliasjon

/ Anne Kari Knudsen / Anne-Tove Brenne
Onkologi / Hematologi

The SPARTAN study – the treatment of non-metastatic castration-resistant prostate cancer

/ Eric J. Small
Onkologi / Hematologi

Multiple myeloma and therapeutic decisions during COVID-19

Promising data for patients with inoperable, locally advanced stage III non-small cell lung cancer

Pembrolizumab in first-line therapy improves survival independent of PD-L1 expression and brain metastases in patients with NSCLC

Adjuvant treatment with osimertinib in patients with stage IB-IIIA EGFR-positive NSCLC after complete tumor resection reduces the risk of relapse and death by 83%

Only few patients have non-metastatic castration-resistant prostate cancer after PET scan

Nivolumab in combination with ipilimumab as first-line treatment of patients with NSCLC continues to show an improved overall survival

Prostate specific antigen decline in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)

ASCO20: we ‘Unite and Conquer’ virtually

Hent flere
Back to top